Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01596751
Recruitment Status : Active, not recruiting
First Posted : May 11, 2012
Last Update Posted : May 31, 2018
Susan G. Komen Breast Cancer Foundation
Information provided by (Responsible Party):
Hope Rugo, MD, University of California, San Francisco

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Actual Primary Completion Date : July 5, 2017
  Estimated Study Completion Date : December 2020